Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | QDPR | P09417 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 3/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310046 | 0.91 | PDE4B (0.62) | PDE4BMEN1KMT2ASTSNAMPT | |
| SCHEMBL30957975 | 0.91 | PDE4B (0.62) | PDE4BMEN1KMT2ASTSNAMPT | |
| SCHEMBL30778326 | 0.88 | NAMPT (0.54) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL15157112 | 0.88 | NAMPT (0.54) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL19115170 | 0.87 | PDE4B (0.63) | PDE4BMEN1KMT2ASTSNAMPT | |
| SCHEMBL24792692 | 0.85 | NAMPT (0.52) | PDE4BNAMPTQDPRKDM4EMAPT | |
| SCHEMBL31130020 | 0.85 | NAMPT (0.52) | PDE4BKMT2ANAMPTKDM4EMAPT | |
| SCHEMBL29751778 | 0.85 | NAMPT (0.52) | PDE4BNAMPTQDPRKDM4EMAPT | |
| SCHEMBL30761541 | 0.85 | PDE4B (0.56) | PDE4BMEN1KMT2ASTSNAMPT | |
| SCHEMBL3988015 | 0.84 | DPP4 (0.52) | PDE4BNAMPTKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | PDE4B 305/4885MEN1 3480/4885KMT2A 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.